Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 8/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14810037 | 0.71 | CYP11B2 (1.00) | CYP11B2CYP11B1NPC1LMNARAB9A | |
| SCHEMBL14810129 | 0.70 | CYP11B2 (0.68) | CYP11B2CYP11B1 | |
| SCHEMBL12668351 | 0.67 | CYP11B2 (0.38) | CYP11B2CYP11B1NPC1LMNARAB9A | |
| SCHEMBL13943628 | 0.67 | MAPT (0.35) | LMNA | |
| SCHEMBL13114252 | 0.66 | CYP11B2 (0.57) | CYP11B2CYP11B1NPC1LMNARAB9A | |
| SCHEMBL9019949 | 0.60 | NPC1 (0.45) | CYP11B2CYP11B1NPC1LMNARAB9A | |
| SCHEMBL23034290 | 0.60 | CYP11B2 (0.33) | CYP11B2CYP11B1NPC1LMNARAB9A | |
| SCHEMBL19207845 | 0.60 | CYP11B2 (0.38) | CYP11B2CYP11B1RAB9ACRBNDDB1 | |
| SCHEMBL21086729 | 0.59 | CRBN (0.37) | CYP11B2CYP11B1NPC1LMNARAB9A | |
| SCHEMBL25247849 | 0.59 | NPC1 (0.35) | CYP11B2CYP11B1NPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9844553-B2 | Pyrazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170020879-A1 | PYRAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020879-A1 | PYRAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B2, CYP11B1 | CYP11B2 2/4885CYP11B1 3/4885NPC1 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.